AME vs AXON

AME exhibits strong financial health with a Piotroski F-Score of 7/9, indicating solid operational performance and earnings quality. However, the stock trades at a significant premium to both the Graham Number ($80.57) and intrinsic value estimate ($127.46), currently priced at $220.74, which reflects high growth expectations not fully supported by near-term growth metrics. While profitability and margin efficiency are well above sector averages, insider selling activity and stretched valuation multiples present cautionary signals. The lack of Altman Z-Score data prevents a full distress risk assessment, but low debt levels suggest limited near-term solvency concerns.

AXON's Advanced Deterministic Scorecard shows a Piotroski F-Score of 6/9, indicating stable financial health, but the absence of an Altman Z-Score limits distress risk assessment. The stock trades at a significant premium to both the Graham Number ($52.48) and intrinsic value ($22.33), supported by strong revenue growth (30.6% YoY) and consistent earnings beats, though recent negative EPS growth and insider selling raise concerns. Profitability is mixed with a healthy gross margin (60.36%) but negative operating and asset returns (ROA: -0.03%, Operating Margin: -0.23%). Analysts maintain a 'buy' recommendation with a $815 target, implying 33% upside, but insider sentiment is bearish, and technical trend is neutral to weak.